Abstract
BackgroundThe TRICC0808 trial is a phase II multi-institutional trial that investigated the efficacy of preoperative mFOLFOX6 + bevacizumab (BV) therapy for liver-only metastasis that is unsuitable for upfront resection. The R0 resection rate in the efficacy analysis has been reported to be 44.4%, and the final analysis for survival was conducted (data fixation on February 16, 2015).MethodsSix cycles of mFOLFOX6 + BV therapy were applied to patients with liver-only metastases, which were > 5 cm in diameter or more than four tumors (H2 and H3), and hepatectomy was performed if possible. Primary and secondary endpoints were the R0 hepatectomy rate and overall survival (OS), respectively.ResultsOf 46 patients registered, OS was analyzed for 45 patients in whom the 3-year OS rate from the starting date of chemotherapy was 44.0% with a 33.6-month median survival time (MST). The 3-year OS rate of 31 patients with hepatectomy, including resection after an additional chemotherapy, was 61.3% with a 43.1-month MST, which was significantly better than 0% of the 3-year OS rate with a 21.0-month MST of 14 patients without hepatectomy (p value < 0.0001). In 24 patients who underwent hepatectomy after six cycles of protocol chemotherapy, the 3-year relapse-free survival rate was 8.3%, with a 36.8-month MST.ConclusionsThis final analysis of the TRICC0808 trial revealed a better long-term survival in patients with hepatectomy after mFOLFOX6 + BV therapy, although most examined patients eventually developed recurrence. Thus, hepatectomy after chemotherapy might improve the survival in patients with advanced liver metastases, although cure remains difficult.
Highlights
Hepatectomy after chemotherapy might improve the survival in patients with advanced liver metastases, cure remains difficult
The liver is a frequent site of metastases from colorectal cancer [1,2,3], and hepatectomy is the only curative treatment, with a 5-year survival rate of 40–60% [3,4,5,6,7]
Only a minority of patients with liver metastases are initially eligible for radical hepatectomy [8]
Summary
The liver is a frequent site of metastases from colorectal cancer [1,2,3], and hepatectomy is the only curative treatment, with a 5-year survival rate of 40–60% [3,4,5,6,7]. Only a minority of patients with liver metastases are initially eligible for radical hepatectomy [8]. In patients with multiple or large liver metastases, liver tumors might not be completely resected or recurrence even after R0 hepatectomy is frequently observed. In the treatment of patients with unresectable liver metastases, conversion therapy has been applied to decrease the tumor size and facilitate resection via preoperative chemotherapy with new potent drugs [17,18,19]. The R0 resection rate in the efficacy analysis has been reported to be 44.4%, and the final analysis for survival was conducted (data fixation on February 16, 2015)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
